Full Text Journal Articles in
Journal Clin Cancer Res

Advertisement

Find full text journal articles






Metabolic alterations and WNT signaling impact immune response in HGSOC.

Rebecca C Arend, Carly B Scalise, Emily R Gordon, Allison M Davis, McKenzie E Foxall, Bobbi E Johnston, David K Crossman, Sara J Cooper,

<h4>Purpose</h4>Our study used transcriptomic and metabolomic strategies to determine the molecular profiles of HGSOC patient samples derived from primary tumor and ascites cells. These data identified clinically relevant heterogeneity among and within patients and highlighted global and patient-specific cellular responses to neoadjuvant chemotherapy (NACT).<h4>Experimental design</h4>Tissue from 61 treatment naïve patients ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Cabozantinib Plus Nivolumab Phase I Expansion Study in Metastatic Urothelial Carcinoma Patients Refractory to Immune Checkpoint Inhibitor Therapy.

Daniel M Girardi, Scot A Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K Pal, Biren Saraiya, Lisa Cordes, Lisa Ley, Olena Sierra Ortiz, Jacqueline Cadena, Carlos Diaz, Hadi Bagheri, Bernadette Redd, Seth M Steinberg, Rene Costello, Keith S Chan, Min-Jung Lee, Sunmin Lee, Yunkai Yu, Sandeep Gurram, Heather J Chalfin, Vladimir Valera, William D Figg, Maria Merino, Antoun Toubaji, Howard Streicher, John J Wright, Elad Sharon, Howard L Parnes, Yang-Min Ning, Donald P Bottaro, Liang Cao, Jane B Trepel, Andrea B Apolo,

<h4>Purpose</h4>This study investigated the efficacy and tolerability of cabozantinib plus nivolumab (CaboNivo) in patients with metastatic urothelial carcinoma (mUC) that progressed on checkpoint inhibition (CPI).<h4>Experimental design</h4>A phase I expansion cohort of mUC patients who received prior CPI was treated with cabozantinib 40 mg/day and nivolumab 3 mg/kg every 2 weeks ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Validation of anti-correlated TGFβ signaling and alternative end-joining DNA repair signatures that predict response to genotoxic cancer therapy.

Ines Guix, Qi Liu, Miguel Angel Pujana, Patrick Ha, Josep Piulats, Isabel Linares, Ferran Guedea, Jian-Hua Mao, Ann Lazar, Jocelyn Chapman, Sue S Yom, Alan Ashworth, Mary Helen Barcellos-Hoff,

<h4>Purpose</h4>Loss of transforming growth factor β (TGFβ) signaling increases error-prone alternative end-joining (alt-EJ) DNA repair. We previously translated this mechanistic relationship as TGFβ and alt-EJ gene expression signatures, which are anti-correlated across cancer types. A score, βAlt, representing anti-correlation predicts patient outcome in response to genotoxic therapy. Here we sought ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models.

Jian L Campian, Subhajit Ghosh, Vaishali Kapoor, Ran Yan, Sukrutha Thotala, Arijita Jash, Tong Hu, Anita Mahadevan, Kasem Rifai, Logan Page, Byung Ha Lee, Sara Ferrando-Martinez, Alexandra A Wolfarth, Se Hwan Yang, Dennis Hallahan, Milan G Chheda, Dinesh Thotala,

<h4>Purpose</h4>Patients with glioblastoma (GBM) are treated with radiation therapy (RT) and temozolomide (TMZ). These treatments may cause prolonged systemic lymphopenia, which itself is associated with poor outcomes. NT-I7 is a long-acting IL-7 that expands CD4 and CD8 T cell numbers in humans and mice. We tested whether NT-I7 prevents systemic ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Integrated analysis of ovarian juvenile granulosa cell tumors reveals distinct epigenetic signatures and recurrent TERT rearrangements.

Theodore Vougiouklakis, Kelsey Zhu, Varshini Vasudevaraja, Jonathan Serrano, Guomiao Shen, Rebecca L Linn, Xiaojun Feng, Sarah Chiang, Julieta E Barroeta, Kristen M Thomas, Lauren E Schwartz, Pratibha S Shukla, Anais Malpica, Esther Oliva, Paolo Cotzia, Deborah F DeLair, Matija Snuderl, George Jour,

<h4>Purpose</h4>Adult granulosa cell tumor (AGCT) is characterized by the somatic <i>FOXL2</i> p.C134W mutation, and recurrences have been associated with <i>TERT</i> promoter and <i>KMT2D</i>-truncating mutations. Conversely, the molecular underpinnings of the rare juvenile granulosa cell tumor (JGCT) have not been well elucidated. To this end, we applied a tumor-only integrated approach ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation.

Ali Bazarbachi, Myriam Labopin, Mahmoud Aljurf, Riitta Niittyvuopio, Marie Balsat, Didier Blaise, Ibrahim Yakoub-Agha, Anna Grassi, Hans Christian Reinhardt, Stig Lenhoff, Pavel Jindra, Jakob Passweg, Iman Abou Dalle, Michael Stadler, Bruno Lioure, Patrice Ceballos, Eolia Brissot, Sebastian Giebel, Arnon Nagler, Christoph Schmid, Mohamad Mohty,

<h4>Purpose</h4>Relapse after allogeneic hematopoietic cell transplantation (allo-HCT) remains the first cause of transplant failure in patients with Philadelphia-positive (Ph<sup>+</sup>) acute lymphoblastic leukemia (ALL). In other hematologic malignancies, therapeutic advances resulted in significant improvement over time in survival of patients relapsing after transplant.<h4>Patients and methods</h4>We compared outcomes at European Society for ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Progress in Transplants for Acute Lymphoblastic Leukemia.

Robert Peter Gale,

Hematopoietic cell transplants are used to treat some adults with acute lymphoblastic leukemia, especially those with high-risk features, such as those with <i>BCR::ABL1.</i> This strategy may be changing given the safety and efficacy of modern tyrosine kinase inhibitors. Although these transplants are often successful, leukemia relapse remains the dominant cause ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Phase 2 Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor.

Peter M Anderson, Matteo M Trucco, Rohinton S Tarapore, Stacey Zahler, Stefanie Thomas, Janette Gortz, Omar Mian, Martin Stoignew, Varun Prabhu, Sara Morrow, Joshua E Allen,

<h4>Purpose</h4>Tumor dopamine-like DRD2 receptor expression is higher in pheochromocytoma-paraganglioma (PC-PG) compared to other cancers. ONC201 is a bitopic DRD2 antagonist with pre-clinical ONC201 activity in DSRCT.<h4>Experimental design</h4>Patients (N=30) with neuroendocrine tumors were treated on this investigator-initiated trial (NCT03034200). ONC201 dose and schedule was 625 mg PO weekly in cohorts A ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



BAMM (BRAF Autophagy and MEK inhibition in Melanoma): A phase I/II trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600-mutant melanoma.

Janice M Mehnert, Tara Mitchell, Alexander C Huang, Tomas S Aleman, Benjamin J Kim, Lynn M Schuchter, Gerald P Linette, Giorgos Karakousis, Sheryl Mitnick, Lydia Giles, Mary Carberry, Noelle Frey, Andrew Kossenkov, Roman Groisberg, Leonel F Hernandez-Aya, George Ansstas, Ann W Silk, Sunandana Chandra, Jeffrey A Sosman, Phyllis A Gimotty, Rosemarie Mick, Ravi Amaravadi,

<h4>Purpose</h4>Autophagy is a resistance mechanism to BRAF/MEK inhibition in <i>BRAFV600-mutant melanoma.</i> Here we used hydroxychloroquine (HCQ) to inhibit autophagy in combination with dabrafenib 150 mg bid and trametenib 2 mg qd (D+T).<h4>Patients and methods</h4>We conducted a phase I/II clinical trial in 4 centers of HCQ+D+T in advanced <i>BRAFV600-mutant</i> melanoma patients. ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



NOTCH induced MDSC recruitment after oHSV virotherapy in CNS cancer models modulates anti-tumor immunotherapy.

Yoshihiro Otani, Ji Young Yoo, Cole T Lewis, Samantha Chao, Jessica Swanner, Toshihiko Shimizu, Jin Muk Kang, Sara A Murphy, Kimberly Rivera-Caraballo, Bangxing Hong, Joseph C Glorioso, Hiroshi Nakashima, Sean E Lawler, Yeshavanthh Banasavadi-Siddegowda, John D Heiss, Yuanqing Yan, Guangsheng Pei, Michael A Caliguri, Zhongming Zhao, E Antonio Chiocca, Jianhua Yu, Balveen Kaur,

<h4>Purpose</h4>Oncolytic herpes simplex virus-1 (oHSV) infection of brain tumors activates NOTCH, however the consequences of NOTCH on oHSV induced immunotherapy is largely unknown. Here we evaluated the impact of NOTCH blockade on virus induced immunotherapy.<h4>Experimental design</h4>RNA sequencing (RNA-seq), TCGA data analysis, flow cytometry, Luminex- and ELISA-based assays, brain tumor animal ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer who underwent Adjuvant Osimertinib in the phase III ADAURA trial.

Margarita Majem, Jonathan W Goldman, Thomas John, Christian Grohe, Konstantin Laktionov, Sang-We Kim, Terufumi Kato, Huu Vinh Vu, Shun Lu, Shanqing Li, Kye Young Lee, Charuwan Akewanlop, Chong-Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Domine, Frances A Shepherd, Shinji Atagi, Lingmin Zeng, Dakshayini Kulkarni, Nenad Medic, Masahiro Tsuboi, Roy S Herbst, Yi-Long Wu,

<h4>Purpose</h4>In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (<i>EGFR</i>m) non-small cell lung cancer (NSCLC). We report health-related quality of life (HRQoL) outcomes from ADAURA.<h4>Experimental design</h4>Patients ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-transplant Myeloma Patients.

Krina K Patel, Jatin J Shah, Lei Feng, Hans C Lee, Elisabet E Manasanch, Jasper Olsem, Ashley Morphey, Xiao Jiao Huo, Sheeba K Thomas, Qaiser Bashir, Muzaffar H Qazilbash, Donna M Weber, Robert Z Orlowski,

<h4>Purpose</h4>In this study, the addition of ixazomib to lenalidomide maintenance post- autologous stem cell transplant (ASCT) in 64 newly diagnosed multiple myeloma (NDMM) patients was evaluated based on the observed benefit of lenalidomide-only maintenance in prior studies.<h4>Methods</h4>Patients were started on maintenance therapy with lenalidomide and ixazomib within 60-180 days of ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study.

Samuel Rosner, Alexander I Spira,

Emerging therapies have recently received approval for the treatment of MET exon 14 skipping non-small cell lung cancer (NSCLC). Further characterization of these therapies, such as tepotinib, is needed to identify patient subgroups most likely to derive benefit from these novel agents.<i>See related article by Le et al., p. XXXX</i>. ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.

Alex F Herrera, Manish R Patel, John M Burke, Ranjana Advani, Bruce D Cheson, Jeff P Sharman, Elicia Penuel, Andrew G Polson, Chen Di Liao, Chunze Li, Eva Schuth, Anjali Vaze, Divya Samineni, Rebecca Elstrom, James Cooper, Catherine Diefenbach,

<h4>Purpose</h4>Targeting CD79B using antibody-drug conjugates (ADC) is an effective therapeutic strategy in B-cell non-Hodgkin lymphoma (B-NHL). We investigated DCDS0780A, an anti-CD79B ADC with THIOMAB{trade mark, serif} technology (TDC) that consistently conjugates two anti-neoplastic molecules per antibody, in contrast to ADCs with heterogeneous loads.<h4>Patients and methods</h4>This phase 1 study enrolled 60 ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Predictive and therapeutic implications of a novel PLCγ1/SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancer.

Raquel Cruz-Duarte, Cátia R de Almeida, Magda Negrão, Afonso Fernandes, Paula Borralho, Daniel Sobral, Lina M Gallego-Paez, Daniel Machado, João Gramaça, José Vílchez, Ana T Xavier, Miguel Godinho Ferreira, Ana R Miranda, Helder Mansinho, Maria J Brito, Teresa R Pacheco, Catarina Abreu, Ana Lucia-Costa, André Mansinho, Rita Fior, Luís Costa, Marta Martins,

<h4>Purpose</h4>Cetuximab is an epidermal growth factor receptor (EGFR)-targeted therapy approved for the treatment of <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC). However, about 60% of these patients show innate resistance to cetuximab. To increase cetuximab efficacy, is crucial to successfully identify responder patients, as well as to develop new therapeutic ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms.

James R Larkin, Susan Anthony, Vanessa A Johanssen, Tianrong Yeo, Megan Sealey, Abi G Yates, Claire Friedemann Smith, Timothy D W Claridge, Brian D Nicholson, Julie-Ann Moreland, Fergus Gleeson, Nicola R Sibson, Daniel C Anthony, Fay Probert,

<h4>Purpose</h4>Early diagnosis of cancer is critical for improving patient outcomes, but cancers may be hard to diagnose if patients present with nonspecific signs and symptoms. We have previously shown that nuclear magnetic resonance (NMR) metabolomics analysis can detect cancer in animal models and distinguish between differing metastatic disease burdens. Here, ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.

Lora Hamuro, Zheyi Hu, Julie Passarell, Heather Barcomb, Joshua Zhang, Shay Goldstein, Akintunde Bello, Amit Roy, Li Zhu,

<h4>Purpose</h4>A benefit:risk assessment for a less-frequent nivolumab 480 mg Q4W + cabozantinib 40 mg QD dosing regimen was predicted using modeling and simulation of clinical trial data from nivolumab monotherapy studies and from the nivolumab 240 mg Q2W + cabozantinib 40mg QD dosing regimen, which demonstrated clinical benefit versus sunitinib ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Genetic subtyping and phenotypic characterization of the immune microenvironment and MYC/BCL2 double expression reveal heterogeneity in diffuse large B-cell lymphoma.

Zijun Y Xu-Monette, Li Wei, Xiaosheng Fang, Qingyan Au, Harry Nunns, Máté Nagy, Alexandar Tzankov, Feng Zhu, Carlo Visco, Govind Bhagat, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D Hsi, Fredrick B Hagemeister, Xiaoping Sun, Xin Han, Heounjeong Go, Maurilio Ponzoni, Andrés J M Ferreri, Michael B Møller, Benjamin M Parsons, J Han van Krieken, Miguel A Piris, Jane N Winter, Yong Li, Bing Xu, Hua You, Maher Albitar, Ken H Young,

<h4>Purpose</h4>Diffuse large B-cell lymphoma (DLBCL) is molecularly and clinically heterogeneous, and can be subtyped according to genetic alterations, B cell-of-origin or microenvironmental signatures using high-throughput genomic data at the DNA or RNA level. Although high-throughput proteomic profiling has not been available for DLBCL subtyping, MYC/BCL2 protein double-expression (DE) is an ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Circulating CD137+ T cells correlate with improved response to anti-PD1 immunotherapy in cancer patients.

Ilaria Grazia Zizzari, Alessandra Di Filippo, Andrea Botticelli, Lidia Strigari, Angelina Pernazza, Emma Rullo, Maria Gemma Pignataro, Alessio Ugolini, Fabio Scirocchi, Francesca Romana Di Pietro, Ernesto Rossi, Alain Gelibter, Giovanni Schinzari, Giulia d'Amati, Aurelia Rughetti, Paolo Marchetti, Marianna Nuti, Chiara Napoletano,

<h4>Purpose</h4>CD137 molecule is expressed by activated lymphocytes, and in cancer patients identifies the tumor-reactive Tcells. In solid tumors, high levels of circulating CD137<sup>+</sup>Tcells are associated with the clinical response and the disease-free status. Here, we examined the role of the CD137<sup>+</sup>Tcells in the improvement of patients' selection for immunotherapy treatment.<h4>Experimental ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Sapanisertib Plus Fulvestrant in Post-Menopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer After Progression on Aromatase Inhibitor.

José Á García-Sáenz, Noelia Martínez-Jáñez, Ricardo Cubedo, Yolanda Jerez, Ainhara Lahuerta, Santiago González-Santiago, Nieves Ferrer, Manuel Ramos, Jose L Alonso-Romero, Antonio Antón, Eva Carrasco, Jingjing Chen, Rachel Neuwirth, Kevin Galinsky, Sylvie Vincent, E Jane Leonard, Dennis Slamon,

<h4>Purpose</h4>This phase II study investigated daily (QD) or weekly (QW) sapanisertib (a selective dual inhibitor of mTOR complexes 1 and 2) in combination with fulvestrant.<h4>Experimental design</h4>Post-menopausal women with estrogen-receptor positive (ER+)/HER2- advanced or metastatic breast cancer following progression during/after aromatase inhibitor treatment were randomized to receive fulvestrant 500 mg (28-day ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, :]

Cited: 0 times

View full text PDF listing >>



Selected Articles from This Issue.

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2022, 28(1):1]

Cited: 0 times

View full text PDF listing >>



Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).

Andrew B Nixon, Susan Halabi, Yingmiao Liu, Mark D Starr, John C Brady, Ivo Shterev, Bin Luo, Herbert I Hurwitz, Phillip G Febbo, Brian I Rini, Himisha Beltran, Eric J Small, Michael J Morris, Daniel J George,

<h4>Purpose</h4>CALGB 90206 was a phase III trial of 732 patients with metastatic renal cell carcinoma (mRCC) comparing bevacizumab plus IFNα (BEV + IFN) with IFNα alone (IFN). No difference in overall survival (OS) was observed. Baseline samples were analyzed to identify predictive biomarkers for survival benefit.<h4>Patients and methods</h4>A total of ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Long term follow-up and patterns of response, progression and hyperprogression in patients after PD-1 blockade in advanced sarcoma.

Nicholas D Klemen, Sinchun Hwang, Martina Bradic, Evan Rosenbaum, Mark A Dickson, Mrinal M Gounder, Ciara M Kelly, Mary Louise Keohan, Sujana Movva, Katherine A Thornton, Ping Chi, Benjamin A Nacev, Jason E Chan, Edmund K Bartlett, Allison L Richards, Samuel Singer, Mark T A Donoghue, William D Tap, Sandra P D'Angelo,

<h4>Purpose</h4>PD-1 blockade can mediate objective responses in advanced sarcomas, but their durability has not been established and it is unclear if hyperprogressive disease (HPD) occurs in sarcomas treated with PD-1 inhibitors.<h4>Methods</h4>We pooled patients who were treated prospectively with nivolumab or pembrolizumab as monotherapy or with bempegaldesleukin, epacadostat, ipilimumab or Talimogene ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Transcriptomic Determinants of Response to Pembrolizumab Monotherapy Across Solid Tumor Types.

Razvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, Andrew Albright, Julie Kobie, Lingkang Huang, Qing Zhao, Anran Wang, Hua Ma, Z Alexander Cao, Michael Morrissey, Antoni Ribas, Petros Grivas, David W Cescon, Terrill K McClanahan, Alexandra Snyder, Mark Ayers, Jared Lunceford, Andrey Loboda,

<h4>Purpose</h4>To explore relationships between biological gene expression signatures and pembrolizumab response.<h4>Experimental design</h4>RNA sequencing data on baseline tumor tissue from 1188 patients across seven tumor types treated with pembrolizumab monotherapy in nine clinical trials were used. A total of eleven prespecified gene expression signatures (18-gene T-cell-inflamed gene expression profile [Tcell<sub>inf</sub>GEP], angiogenesis, ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).

Andrew B Nixon, Alexander B Sibley, Yingmiao Liu, Ace J Hatch, Chen Jiang, Flora Mulkey, Mark D Starr, John C Brady, Donna Niedzwiecki, Alan P Venook, Luis Baez-Diaz, Heinz-Josef Lenz, Bert H O'Neil, Federico Innocenti, Jeffrey A Meyerhardt, Eileen M O'Reilly, Kouros Owzar, Herbert I Hurwitz,

<h4>Purpose</h4>CALGB 80405 compared the combination of first-line chemotherapy with cetuximab or bevacizumab in the treatment of advanced or metastatic colorectal cancer (mCRC). Although similar clinical outcomes were observed in the cetuximab-chemotherapy group and the bevacizumab-chemotherapy group, biomarkers could identify patients deriving more benefit from either biologic agent.<h4>Patients and methods</h4>In this ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.0073 s